Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 773-778

  Look, K Y ^a,g   Blessing, J A ^b   Michener, C M ^c   Rubin, S C ^d   Ramirez, P T ^e   Mackey, Denise ^f  

^a INDIANA UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f GOG Administrative Office   (United States)

^g Eli Lilly ^*

Author keywords

Capecitabine; Nonsquamous cervical carcinoma

Indexed keywords

CAPECITABINE; DERMATOLOGICAL AGENT; DIPHENOXYLATE; LOPERAMIDE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SEPSIS; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 47649126533     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01080.x     Document Type: Article

References (28)

1. Ferlay J, Bray F, Piisani I, Parkin DM. Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC cancerbase no.5, version 2.0. Lyon : IARC Press, 2004.
2. Smith HO, Tiffany MF, Qualls CR, Keys CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecol Oncol 2000 78 : 97 105.
3. Rose PG, Bundy BN, Watkins JT et al. Concurrent cisplatin based chemotherapy and radiotherapy for locally advanced cervical cancer. N Eng J Med 1999 340 : 1144 53.
4. Whitney C, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999 17 : 1339 48.
5. Thigpen JT, Blessing JA, Fowler WC, Hatch K. Phase II trials of cisplatin and piperazinedione as a single agent in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1986 70 : 1097 100.
6. Sutton GP, Blessing JA, DiSaia PJ, McGuire WP. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1993 49 : 48 50.
7. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel an active agent in non-squamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2001 19 : 1275 8.
8. Look KY, Blessing JA, Valea FA et al. Phase II trial of 5-fluorouracil and high dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1997 67 : 255 8.
9. Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th edn. New York, NY : McGraw-Hill Medical Publishing Division, 2001 : 1404 8.
10. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001 12 : 1247 54.
11. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane pretreated metastatic breast carcinoma patients. Cancer 2001 92 : 1759 68.
12. Walsh JW, Amendola MA, Hall DJ, Tisnado J, Goplerud DR. Recurrent carcinoma of the cervix: CT diagnosis. Am J Roentgenol 1981 136 : 117 22.
13. Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Int Med 1973 79 : 604 5.
14. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005 16 : 1289 96.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Cancer. J Natl Cancer Inst 2000 92 : 205 16.
16. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Met 1998 17 : 2301 12.
17. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001 19 : 4097 106.
18. Long HJ, Bundy BN, Grendys EC Jr. et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005 23 : 4626 33.
19. Jenkins AD, Ramondetta LM, Sun C et al. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2005 97 : 840 4.
20. Garcia AA, Blessing JA, Lenz HJ et al. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 2005 96 : 810 7.
21. Rischin D, Phillips KA, Friedlander M et al. A phase II trial of capecitabine in heavily pre-treated platinum resistant ovarian cancer. Gynecol Oncol 2004 93 : 417 21.
22. Garcia A, Blessing J, Darcy KM et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynecologic Oncology Group study. Gynecol Oncol 2007 104 : 572 9.
23. Leichman CG, Lenz HJ, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion 5-fluorouracil and weekly leucovorin. J Clin Oncol 1997 15 : 3223 9.
24. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low expression levels of dihydopyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 6 : 1322 7.
25. Takebayashi Y, Yamada K, Miyadera K et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 1996 32A : 1227 32.
26. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998 34 : 1274 81.
27. Oguri H, Maeda N, Yamamoto Y, Kusume T, Fukaya T. Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma. Cancer Chemother Pharmacol 2004 53 : 151 4.
28. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005 96 : 103 7.